TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Artelo Biosciences ( (ARTL) ).
On November 19, 2025, Artelo Biosciences received a delist determination letter from Nasdaq due to non-compliance with Listing Rule 5550(b)(1), which requires maintaining stockholders’ equity of at least $2,500,000. Despite submitting plans to regain compliance, the company failed to raise the necessary capital. Artelo intends to appeal the decision to prevent delisting, allowing its stock to continue trading under the symbol ‘ARTL’ while the appeal is pending.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. operates within the biotechnology industry, focusing on the development of therapeutics for cancer, pain, and inflammation.
Average Trading Volume: 234,379
Technical Sentiment Signal: Sell
Current Market Cap: $3.59M
For an in-depth examination of ARTL stock, go to TipRanks’ Overview page.